Repetitive transcranial magnetic stimulation as a prophylactic treatment in migraine

Table 4 Comparison between 4 weeks pre- and 4 weeks post-TMS as regards clinical data of migraine, MIDAS, and serum levels of neurokinin A in group B (migraine with aura)

		With aura		Test value	P value
		Pre-TMS, no. = 10	Post-TMS, no. = 10	Test value	P value
Neurokinin A serum level	Mean ± SD	23.64 ± 1.87	13.09 ± 3.58	− 2.803^•	0.005
Neurokinin A serum level	Range	20.46–26.45	9.69–22.55	− 2.803^•	0.005
No. of headache attacks (days per month)	Median (IQR)	16.50 (15.00–20.00)	3.00 (2.00–6.00)	− 2.807^ǂ	0.005
No. of headache attacks (days per month)	Range	12.00–21.00	0.00–20.00	− 2.807^ǂ	0.005
Duration of individual attack (hours)	Median (IQR)	15.00 (12.25–25.50)	.25 (0.13–0.69)	− 2.803^ǂ	0.005
Duration of individual attack (hours)	Range	4.75–28.50	0.00–13.00	− 2.803^ǂ	0.005
No. of pills (per month)	Median (IQR)	19.50 (12.00–26.00)	0.00 (0.00–0.00)	− 2.666^ǂ	0.008
No. of pills (per month)	Range	0.00–36.00	0.00–20.00	− 2.666^ǂ	0.008
Pain intensity	Median (IQR)	7.50 (7.25–7.75)	.75 (0.50–2.00)	− 2.812^ǂ	0.005
Pain intensity	Range	6.50–8.50	0.00–7.00	− 2.812^ǂ	0.005
MIDAS score	Median (IQR)	35.00 (22.00–46.00)	2.00 (0.00–4.00)	− 2.705^ǂ	0.007
MIDAS score	Range	17.00–49.00	0.00–47.00	− 2.705^ǂ	0.007

P value > 0.05, non-significant (NS); P value < 0.05, significant (S); P value < 0.001, highly significant (HS)
^•Paired t test
^ǂWilcoxon’s rank test